Neurocrine Biosciences, Inc.
NBIX
$151.39
-$1.09-0.72%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 15.62% | 20.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.62% | 20.07% | |||
| Cost of Revenue | 3.29% | -6.17% | |||
| Gross Profit | 22.92% | 43.87% | |||
| SG&A Expenses | 1.85% | 3.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.53% | -1.28% | |||
| Operating Income | 64.35% | 514.35% | |||
| Income Before Tax | 82.95% | 985.03% | |||
| Income Tax Expenses | 58.27% | 664.71% | |||
| Earnings from Continuing Operations | 94.88% | 1,260.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 94.88% | 1,260.76% | |||
| EBIT | 64.35% | 514.35% | |||
| EBITDA | 61.54% | 388.50% | |||
| EPS Basic | 94.09% | 1,271.09% | |||
| Normalized Basic EPS | 56.71% | 268.66% | |||
| EPS Diluted | 92.45% | 1,238.38% | |||
| Normalized Diluted EPS | 55.03% | 271.57% | |||
| Average Basic Shares Outstanding | 0.40% | -0.70% | |||
| Average Diluted Shares Outstanding | 1.49% | -1.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||